HOME >> BIOLOGY >> NEWS
Incubator company at NJIT develops lifesaving MRI coil for small animals

NEWARK, Mar 7-Supertron, a start-up technology company housed in the small business incubators at New Jersey Institute of Technology (NJIT, announced today that it has begun developing a cryogenic coil to improve Magnetic Resonance Imaging (MRI) scanners.

"The new coil will be well suited for animal imaging," said Supertron President Jon T. DeVries. "Small animal models, particularly genetically engineered mice, are becoming an increasingly powerful tool for cancer researchers. This potential has not been fully realized to date due to the need to sacrifice the animal and conduct tissue and molecular analysis thereby losing out on the opportunity to observe, in vivo, the evolution of the processes under study."

The New Jersey Economic Development Authority (NJEDA) recently awarded the company a $250,000 Springboard II grant. This money follows an earlier $2 million grant in 2003 from the National Institute of Science and Technology (NIST) at the US Department of Commerce.

Erzhen Gao, PhD, director of research and development for the company will lead the effort. The tests will be conducted through a series of animal studies conducted at University of Medicine and Dentistry of New Jersey (UMDNJ).

"Eventually, we hope to see our system upgrade existing MRI scanners because our coils can enhance installed MRIs, enabling them to produce cleaner, clearer and easier-to-read images at an affordable price," said DeVries. A medical school is testing another Supertron coil system developed for low field MRIs of the human head.

DeVries said interest in small animal imaging is growing and cited programs doing this research including the Small Animal Imaging Resource Program at the National Cancer Institute.

Coils are the receiving antenna of the radio waves emitted during an MRI scan and are essential to the MRI's operation. An MRI clinic may have as many as ten coils, each designed for specific anatomical parts (spine, he
'"/>

Contact: Sheryl Weinstein
sheryl.m.weinstein@njit.edu
973-596-3436
New Jersey Institute of Technology
7-Mar-2005


Page: 1 2 3

Related biology news :

1. Colorado company to sell medical food products based on Wake Forest discovery
2. Spin-out company seeks medicines from South American rain forests
3. New company will seek drugs against diabetes and cancer
4. EMBL scientists found start-up company to develop anti-cancer drugs
5. New waste water technology company wins 2006 EUREKA Lynx Award
6. Yale technology spins out varicose vein device company: Vascular Insights, LLC
7. Innovative technology for production of new pharmaceuticals forms basis of new company
8. Ossur acquires US orthotics company Royce Medical
9. USF spin-out company Saneron CCEL wins federal award for cell therapy
10. Idaho lab, Utah company achieve major milestone in hydrogen research
11. N.C. A&T food scientist develops process for allergen-free peanuts

Post Your Comments:
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
Cached News: